Last Updated on 2026 年 3 月 18 日 by 総合編集組
Global Diabetes Epidemic 2024-2035: 589 Million Patients, $1.437 Trillion Market, Breakthrough GLP-1 Drugs and Regenerative Cures Explained
The world is witnessing an unprecedented rise in diabetes cases, yet the medical community is responding with remarkable innovations that promise better management and even potential cures. As of 2024, approximately 589 million adults aged 20-79 are living with diabetes, representing 11.11% of the global adult population. Projections indicate this number will climb to 853 million by 2050, a 46% increase.
This detailed overview explores the latest epidemiology, emerging youth-onset trends, revolutionary incretin-based therapies, regenerative medicine breakthroughs, market forecasts through 2035, and specific insights for Taiwan and the Asia-Pacific region. All information draws from authoritative sources like the International Diabetes Federation and recent clinical trials, offering readers a comprehensive yet accessible guide to understand both the challenges and the exciting solutions ahead.
Section 1: Understanding the Global Scale and Regional Patterns Diabetes is no longer just a condition affecting older adults; its structural evolution reflects aging populations, rapid urbanization, and lifestyle shifts. Currently, over 81% of cases occur in low- and middle-income countries, where the prevalence rate stands at 11.46% in middle-income nations, compared to 10.21% in high-income countries and 7.47% in low-income ones. A striking statistic is that more than 252 million people worldwide remain undiagnosed, often leading to late-stage complications such as retinopathy or kidney disease.
By age group, the condition shows a strong correlation: in the 75-79 age bracket, prevalence reaches 24.79%, meaning roughly one in four elderly individuals is affected. Men experience a slightly higher rate (11.55%) than women (10.68%), and urban dwellers (12.26%) face greater risk than rural populations (9.23%). These patterns underscore how modern city life, with sedentary jobs and high-calorie delivery foods, accelerates metabolic imbalance.
Looking ahead, the adult prevalence rate is expected to rise from 11.11% in 2024 to 12.96% by 2050. Intermediate milestones include 643 million patients in 2030 and 783 million in 2045. This growth trajectory highlights the urgent need for scalable prevention and treatment strategies that can adapt across economic and geographic divides.
Section 2: The Alarming Rise of Youth-Onset Type 2 Diabetes One of the most concerning developments is the spread of Type 2 diabetes into younger populations. Between 1990 and 2021, the global incidence rate for ages 15-24 jumped from 56.0 to 123.9 cases per 100,000 people, with an average annual percent change of 2.62%. Prevalence in the same group more than doubled from 357.3 to 773.0 per 100,000. In the United States, without major public health interventions, the number of patients under 20 could surge 700% by 2060, reaching approximately 220,000 individuals.
Young-onset Type 2 diabetes often progresses more aggressively than adult-onset cases. Beta-cell function declines faster, and insulin resistance is more pronounced—sometimes 50% lower sensitivity than in adults of similar body mass index. Within five years of diagnosis, microvascular complications spike dramatically; retinopathy prevalence, for example, can rise from 1.11% at initial diagnosis to 28.14%. This early onset threatens long-term productivity and demands extended chronic care planning.
Contributing factors include high body mass index, sedentary lifestyles, genetic predisposition, and the obesogenic environment filled with ultra-processed foods. Maternal exposure to gestational diabetes further elevates risk during adolescence. Addressing these through early screening and lifestyle education could significantly alter future trajectories.
Section 3: The Shift to Incretin-Based Therapies and Multi-Target Agonists Treatment paradigms have moved beyond simple glucose lowering toward comprehensive metabolic management. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their multi-receptor counterparts now lead the field by mimicking natural gut hormones while delivering cardiovascular, kidney, and liver protection.
At the molecular level, GLP-1 receptors belong to the B-class G-protein-coupled family. Activation boosts intracellular cyclic AMP, triggering protein kinase A and Epac2 pathways that promote insulin release only when glucose is elevated—minimizing hypoglycemia risk. These receptors are also present in the heart, kidneys, lungs, and central nervous system, where they suppress NF-κB signaling to reduce systemic inflammation.
Several pipeline candidates are poised for major approvals between 2025 and 2027. Novo Nordisk’s high-dose oral semaglutide (25 mg and 50 mg) demonstrated 13.6% average weight loss over 64 weeks in the OASIS-4 trial. Eli Lilly’s tirzepatide, a dual GLP-1/GIP agonist, achieved liver inflammation resolution in 62% of patients in the SYNERGY-NASH study for metabolic-associated steatohepatitis. Retatrutide, a triple GLP-1/GIP/glucagon agonist, showed 24.2% weight reduction at 48 weeks in Phase 3 data, positioning it as a potential new leader. Smaller-molecule oral options like orforglipron offer daily dosing without refrigeration, lowering production and distribution barriers.
Additional agents include survodutide (GLP-1/glucagon), maritide (GLP-1/GIP receptor antagonist via antibody technology), and cagrisema (GLP-1/amylin). Beyond diabetes and obesity, these compounds show promise for obstructive sleep apnea, Alzheimer’s disease, and addiction. The SELECT trial, for instance, confirmed semaglutide’s ability to rapidly reduce myocardial infarction and stroke risk.
Section 4: Regenerative Medicine and Functional Cure Pathways For Type 1 diabetes and severe insulin-dependent Type 2 cases, 2025 marks a pivotal year for cell and gene therapies. The focus is creating transplantable islets that evade immune attack without lifelong immunosuppression.
Vertex Pharmaceuticals’ VX-880 program (Zimislecel) enabled 10 out of 12 severely affected patients to eliminate insulin injections after one year. The company is scaling production with Lonza and developing CRISPR-edited “hypoimmune” islets by removing MHC complexes. Sana Biotechnology’s gene-edited islets survived 12 weeks in human testing while secreting insulin drug-free.
Kriya Therapeutics’ KRIYA-839 aims to convert skeletal muscle into an insulin factory using AAV vectors. Meanwhile, automated artificial pancreas systems like the iLet Bionic Pancreas integrate AI algorithms with continuous glucose monitors (e.g., Dexcom G7), adjusting doses every five minutes to extend time-in-range and cut nighttime hypoglycemia. These advances signal a transition from lifelong management toward functional cures.
Section 5: Market Projections and Economic Drivers to 2035 The global diabetes drug market is entering a decade-long super-cycle fueled by patient growth, innovative therapies, and improved diagnostics. From an estimated $751.6 billion in 2025, the total is forecast to reach $1,437.6 billion by 2035 at a 6.7% compound annual growth rate. When factoring in GLP-1 expansions into non-diabetes indications, some models project up to $1,668 billion.
The GLP-1 segment alone could expand to between $157.5 billion and $324.5 billion by 2035, potentially becoming the first pharmaceutical class to exceed $100 billion annually. Continuous glucose monitoring will dominate, with traditional finger-stick strips shrinking to just 5.15% market share. Other segments include diabetes management apps growing at 8.54% CAGR to $4.38 billion, healthcare AI surging at 16.2% to $77.2 billion, and the broader digital health market reaching $1,628 billion.
Geographically, the Asia-Pacific region leads growth thanks to urbanization in China, India, and Southeast Asia. The United States remains the highest-value market, projected at $21.97 billion for Type 2 diabetes alone. Patent cliffs—liraglutide generics from 2026 and semaglutide expirations in 2031-2032—will lower prices by up to 70%, improving access in lower-income countries.
Section 6: Taiwan and Asia-Pacific Regional Insights Taiwan stands as a regional leader with over 2.5 million diabetes patients, increasing by about 25,000 annually. By 2030, the figure is expected to hit 3 million—one in every ten residents. The under-40 patient population has grown 25% recently, linked to high-sugar beverages where roughly 70% of bottled drinks exceed WHO limits. Eighty percent of Type 2 cases involve overweight or obesity, and 20% present with kidney disease or retinopathy at diagnosis.
National Health Insurance provides broad coverage but restricts GLP-1 and SGLT2 agents to second-line use and currently excludes obesity-only indications. Parallel review processes have shortened innovation-to-reimbursement timelines. A collaboration with Google uses Gemini AI to analyze data from 1.3 million patients for complication risk prediction, aiming to serve over 2 million by 2026.
Comparative trends across Asia-Pacific show China facing 142 million patients by 2035, Japan driven by aging demographics, and Southeast Asia projected at 113 million cases by 2030 amid infrastructure challenges.
Section 7: Health Economics and Long-Term Value Although monthly GLP-1 costs range from $900 to $1,300, economic models demonstrate strong returns. Combining continuous glucose monitoring with these agents adds roughly $16,000 upfront but yields an incremental cost-effectiveness ratio of $20,825 per quality-adjusted life year—well below typical willingness-to-pay thresholds of $50,000-$100,000. Expected reductions include 17% fewer eye complications, 20% less kidney failure, and 2.4% fewer cardiovascular events.
Broader societal gains—preventing blindness, dialysis, and workforce loss—could preserve up to $4 trillion in global GDP by 2035 according to the World Obesity Federation. Short-term claim growth of 13.01% creates tension, yet value-based reimbursement frameworks are increasingly recognizing the long-term payoff.
Section 8: Strategic Outlook and Practical Recommendations Diabetes is evolving from a manageable chronic condition into a preventable public health success story. Policymakers should prioritize youth obesity interventions via sugar taxes and screening, adopt value-based pricing that rewards organ protection, and expand digital integration. Industry leaders must accelerate oral and small-molecule formulations, bolster supply chains with billion-dollar automated facilities, and commercialize immune-evasive cell therapies.
With these tools, humanity stands better equipped than ever to reverse decades of metabolic challenges. Continued innovation in GLP-1 agents, regenerative medicine, and AI-driven care offers genuine hope for healthier populations worldwide.
